No impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframe Focused investment on high‑value late‑stage assets ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United ...
SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS), a national provider of comprehensive pediatric healthcare, is partnering with Morgan’s to bring its Prescribed Pediatric ...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of ...
Le Document d’enregistrement universel 2025 a été déposé en format ESEF auprès de l’Autorité des Marchés Financiers (AMF) le 27 février 2026, sous le n° D.26-0054. Le Document d’enregistrement ...
The Raymond James 47 th Annual Institutional Investors Conference will take place at the JW Marriott Grande Lakes, Orlando. About RadNet, Inc. RadNet, Inc. is a leading national provider of ...
Louvain-la-Neuve, Belgium, March 2nd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam ...
Lyon (France), le 2 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des ...
See: AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer ...
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by ...
Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting. Investors registered to attend the ...
Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results